Company: ATRA
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0000950170-25-059322
Chunk: 41

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 41
---
ists of 3,100 shares held directly by Mr. Mallik and 6,640 shares pursuant to options exercisable within 60 days of March 14, 2025.

Consists of 16,432 shares held directly by Dr. Nguyen and 20,540 shares pursuant to options exercisable within 60 days of March 14, 2025.

Consists of 14,738 shares held directly by Mr. Murugan.

<div align='center'>25</div>

(15) Consists of 3,540 shares held directly by Dr. Roncarolo and 7,520 shares pursuant to options exercisable within 60 days of March 14, 2025. (16) Includes 108,396 shares issuable pursuant to options exercisable and RSUs expected to vest within 60 days of March 14, 2025. In connection with Mr. Hyllengren's departure from the Company, he relinquished all of his vested and unvested stock options. EXECUTIVE OFFICERS The following table sets forth certain information with respect to our executive officers as of April 28, 2025. Biographical information with regard to Dr. Nguyen is presented under “ Proposal No. 1—Election of Directors ” in this Proxy Statement.

| Name                |     | Age |     | Position(s)                                     |
| AnhCo Nguyen, Ph.D. |     |  52 |     | President, Chief Executive Officer and Director |

EXECUTIVE COMPENSATION As the Company qualifies as a “smaller reporting company” in accordance with Rule 12b‑2 of the Exchange Act, the Company is permitted to comply with scaled-down executive compensation disclosure requirements, including not providing a Compensation Discussion and Analysis (“CD&A”) section in this proxy statement. In order to provide fulsome disclosure to its stockholders and in line with best practices, the Company has elected to include a CD&A but has relied on certain other disclosure relief applicable to smaller reporting companies, such as limiting the number of named executive officers subject to the disclosure and certain of the executive compensation tabular disclosure. Compensation Discussion and Analysis This CD&A explains the strategy, design, and decision-making related to our compensation programs and practices for our principal executive officer, our two other most highly compensated executive officers serving as executive officers as of December 31, 2024, and one former executive officer, referred to collectively as our named executive officers. This CD&A is intended to provide perspective on the